BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27912913)

  • 1. Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid.
    Cuesta-Lasso M; Vieira-Barros A; Dolz-Marco R; Roig-Revert MJ; Badal J; Amselem L; Díaz-Llopis M; Gallego-Pinazo R
    Arch Soc Esp Oftalmol; 2017 Mar; 92(3):101-106. PubMed ID: 27912913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
    Inan S; Polat O; Karadas M; Inan UU
    Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
    [No Abstract]   [Full Text] [Related]  

  • 3. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
    ; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL
    Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.
    Gianniou C; Dirani A; Jang L; Mantel I
    Retina; 2015 Jun; 35(6):1195-201. PubMed ID: 25650710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Prospective Pilot Study.
    Barikian A; Salti H; Safar A; Mahfoud ZR; Bashshur ZF
    Retina; 2017 Jul; 37(7):1337-1344. PubMed ID: 27768640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PREDICTING RESPONSE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION TO BEVACIZUMAB BASED ON SPECTRALIS OPTICAL COHERENCE TOMOGRAPHY.
    Segal O; Barayev E; Nemet AY; Mimouni M
    Retina; 2016 Feb; 36(2):259-63. PubMed ID: 26200510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB.
    Pokroy R; Mimouni M; Barayev E; Segev F; Geffen N; Nemet AY; Segal O
    Retina; 2018 Aug; 38(8):1485-1491. PubMed ID: 28654630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
    Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
    Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
    Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.